Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts - PubMed (original) (raw)
Review
Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts
John W Cassidy et al. Cancer Res. 2015.
Abstract
Preclinical models often fail to capture the diverse heterogeneity of human malignancies and as such lack clinical predictive power. Patient-derived tumor xenografts (PDX) have emerged as a powerful technology: capable of retaining the molecular heterogeneity of their originating sample. However, heterogeneity within a tumor is governed by both cell-autonomous (e.g., genetic and epigenetic heterogeneity) and non-cell-autonomous (e.g., stromal heterogeneity) drivers. Although PDXs can largely recapitulate the polygenomic architecture of human tumors, they do not fully account for heterogeneity in the tumor microenvironment. Hence, these models have substantial utility in basic and translational research in cancer biology; however, study of stromal or immune drivers of malignant progression may be limited. Similarly, PDX models offer the ability to conduct patient-specific in vivo and ex vivo drug screens, but stromal contributions to treatment responses may be under-represented. This review discusses the sources and consequences of intratumor heterogeneity and how these are recapitulated in the PDX model. Limitations of the current generation of PDXs are discussed and strategies to improve several aspects of the model with respect to preserving heterogeneity are proposed.
©2015 American Association for Cancer Research.
Figures
Figure 1
A shows a primary breast tumour including some sources of heterogeneity found in the native microenvironment. Reciprocal signalling pathways between tumour cells and tumour associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) are highlighted. Extracellular matrix (ECM) is shown as collagen fibres with associated fibroblasts and macrophage/dendritic cells with T/B Lymphocytes are shown as part of the immune infiltrate, though other cell types (NK cells, myeloid derived suppressors etc.) have been omitted for simplicity. Panel B highlights patient matched fibroblasts and immune cells as possible candidates for co-engraftment in the next generation of PDX models. Current PDXs established in NSG mice lack an adaptive immune system and may have impaired innate immune cell infiltrates and cytokine signalling due to defective IL-2 receptor (33). Cancer associated fibroblasts are known to contribute to treatment response, although murine fibroblasts are present in PDX models, it is unclear how faithfully these recapitulate their human counterparts (26). Panel C shows a PDX tumour in its native microenvironment. Questions over whether pro- and anti- tumour CAF/TAM signalling pathways are present to the same extent in PDX models as in the primary tumour are highlighted. Stromal and tissue architecture can have profound effects on transcriptional regulation but are often overlooked in the establishment of PDX models (25). To highlight potential differences in ECM organisation between the native microenvironment and that of the PDX, here the ECM is shown as highly organised collagen fibres with closely associated myofibroblasts.
Similar articles
- Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas.
Jakša R, Karolová J, Svatoň M, Kazantsev D, Grajciarová M, Pokorná E, Tonar Z, Klánová M, Winkowska L, Maláriková D, Vočková P, Forsterová K, Renešová N, Dolníková A, Nožičková K, Dundr P, Froňková E, Trněný M, Klener P. Jakša R, et al. Lab Invest. 2022 Sep;102(9):957-965. doi: 10.1038/s41374-022-00784-w. Epub 2022 Apr 29. Lab Invest. 2022. PMID: 35488033 Free PMC article. - Ewing Sarcoma PDX Models.
Surdez D, Landuzzi L, Scotlandi K, Manara MC. Surdez D, et al. Methods Mol Biol. 2021;2226:223-242. doi: 10.1007/978-1-0716-1020-6_18. Methods Mol Biol. 2021. PMID: 33326106 - Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer.
Pu X, Zhang R, Wang L, Chen Y, Xu Y, Pataer A, Meraz IM, Zhang X, Wu S, Wu L, Su D, Mao W, Heymach JV, Roth JA, Swisher SG, Fang B. Pu X, et al. J Transl Med. 2018 Nov 26;16(1):328. doi: 10.1186/s12967-018-1704-3. J Transl Med. 2018. PMID: 30477533 Free PMC article. - Patient-derived xenografts (PDXs) as model systems for human cancer.
Invrea F, Rovito R, Torchiaro E, Petti C, Isella C, Medico E. Invrea F, et al. Curr Opin Biotechnol. 2020 Jun;63:151-156. doi: 10.1016/j.copbio.2020.01.003. Epub 2020 Feb 18. Curr Opin Biotechnol. 2020. PMID: 32070860 Review. - Applications of patient-derived tumor xenograft models and tumor organoids.
Yoshida GJ. Yoshida GJ. J Hematol Oncol. 2020 Jan 7;13(1):4. doi: 10.1186/s13045-019-0829-z. J Hematol Oncol. 2020. PMID: 31910904 Free PMC article. Review.
Cited by
- Immunologically "cold" triple negative breast cancers engraft at a higher rate in patient derived xenografts.
Petrosyan V, Dobrolecki LE, LaPlante EL, Srinivasan RR, Bailey MH, Welm AL, Welm BE, Lewis MT, Milosavljevic A. Petrosyan V, et al. NPJ Breast Cancer. 2022 Sep 10;8(1):104. doi: 10.1038/s41523-022-00476-0. NPJ Breast Cancer. 2022. PMID: 36088362 Free PMC article. - Three-Dimensional Ex Vivo Culture for Drug Responses of Patient-Derived Gastric Cancer Tissue.
Chen S, Chen C, Hu Y, Zhu C, Luo X, Wang L, Wang X, Sun X, Chen X, Xie W, Lou H, Huang X, Li C, Xu J, Xue X, Shen X. Chen S, et al. Front Oncol. 2021 Feb 15;10:614096. doi: 10.3389/fonc.2020.614096. eCollection 2020. Front Oncol. 2021. PMID: 33659211 Free PMC article. - Investigating T Cell Immunity in Cancer: Achievements and Prospects.
Zeng Z, Chew HY, Cruz JG, Leggatt GR, Wells JW. Zeng Z, et al. Int J Mol Sci. 2021 Mar 12;22(6):2907. doi: 10.3390/ijms22062907. Int J Mol Sci. 2021. PMID: 33809369 Free PMC article. Review. - Patient-derived tumour xenografts for breast cancer drug discovery.
Cassidy JW, Batra AS, Greenwood W, Bruna A. Cassidy JW, et al. Endocr Relat Cancer. 2016 Dec;23(12):T259-T270. doi: 10.1530/ERC-16-0251. Epub 2016 Oct 4. Endocr Relat Cancer. 2016. PMID: 27702751 Free PMC article. Review. - BMP2/BMPR1A is linked to tumour progression in dedifferentiated liposarcomas.
O'Neill HL, Cassidy AP, Harris OB, Cassidy JW. O'Neill HL, et al. PeerJ. 2016 Apr 19;4:e1957. doi: 10.7717/peerj.1957. eCollection 2016. PeerJ. 2016. PMID: 27114889 Free PMC article.
References
- Huang M, Shen A, Ding J, Geng M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci. 2014;35:41–50. - PubMed
- Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources